



EXECUTIVE OFFICE OF HEALTH AND HUMAN SERVICES
COMMONWEALTH OF MASSACHUSETTS
 ONE ASHBURTON PLACE, BOSTON, MA 02108
 (617) 573-1600



MAURA T. HEALEY
 GOVERNOR

KATHLEEN E. WALSH
 SECRETARY

KIMBERLEY DRISCOLL
 LIEUTENANT GOVERNOR

MIKE LEVINE
 ASSISTANT SECRETARY
 FOR MASSHEALTH

Administrative Bulletin 24-19

101 CMR 320.00: Rates for Clinical Laboratory Services

Effective January 1, 2024

2024 CPT Code Updates

Summary

In accordance with 101 CMR 320.01(4)(c), the Executive Office of Health and Human Services (EOHHS) is adding new service codes effective for dates of service on and after January 1, 2024. Below are the codes that have been added. The rates in this administrative bulletin will apply until EOHHS issues revised rates.

Added Codes

Codes	Rate	Description
81457	\$0.00	Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, microsatellite instability
81458	\$0.00	Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis, copy number variants and microsatellite instability
81459	\$0.00	Solid organ neoplasm, genomic sequence analysis panel, interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements

Codes	Rate	Description
81462	\$0.00	Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (e.g., plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants and rearrangements
81463	\$0.00	Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (e.g., plasma), interrogation for sequence variants; DNA analysis, copy number variants, and microsatellite instability
81464	\$0.00	Solid organ neoplasm, genomic sequence analysis panel, cell-free nucleic acid (e.g., plasma), interrogation for sequence variants; DNA analysis or combined DNA and RNA analysis, copy number variants, microsatellite instability, tumor mutation burden, and rearrangements
81517	\$155.40	Liver disease, analysis of 3 biomarkers (hyaluronic acid [HA], procollagen III amino terminal peptide [PIIINP], tissue inhibitor of metalloproteinase 1 [TIMP-1]), using immunoassays, utilizing serum, prognostic algorithm reported as a risk score and risk of liver fibrosis and liver-related clinical events within 5 years
82166	\$34.06	Anti-mullerian hormone (AMH)
86041	\$16.23	Acetylcholine receptor (AChR); binding antibody
86042	\$16.23	Acetylcholine receptor (AChR); blocking antibody
86043	\$10.63	Acetylcholine receptor (AChR); modulating antibody
86366	\$16.23	Muscle-specific kinase (MuSK) antibody
87523	\$37.78	Infectious agent detection by nucleic acid (DNA or RNA); hepatitis D (delta), quantification, including reverse transcription, when performed